Substituted pyrimidinyl oxime kinase inhibitors

US8367825B2 · kind B2 · utility

Assignee

• Janssen Pharmaceutica NA · BE

Inventors

• Xu Guozhang · Bensalem, US
• Lily Lee · New York, US
• Terry Vincent Hughes · Blue Bell, US
• Steven K. Wetter · Flemington, US
• Peter J. Connolly · New Providence, US
• Marta C. Abad · Downingtown, US
• Stuart Emanuel · Doylestown, US
• Prabha S. Kamachi · Fryeburg, US
• Steven A. Middleton · Flemington, US
• Kathleen Battista · Williamstown, US
• Gilles Bignan · Bound Brook, US

Key dates

• Filing date: Feb 28, 2012
• Grant date: Feb 5, 2013
• Expiry date: Feb 28, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention is directed to substituted pyrimidine compounds of formula (I):and forms thereof, their synthesis and use for treating, preventing or ameliorating a chronic or acute protein kinase mediated disease, disorder or condition.